Abstracts tagged "major histocompatibility complex (MHC)"

Abstract Number: 123 • 2019 ACR/ARP Annual Meeting
Blockade of Antigen-specific T Cell Activation by a Non-Depleting Anti-HLA-DR Monoclonal Antibody with a Unique Binding Epitope
Fang Shen¹, Karen Duffy ¹, Stephane Becart ², Robert Kuhn ¹, Melissa Swiecki ¹, Brian Jones ¹, Yawei Li ¹, Jeffrey Hall ¹, Ravi Malaviya ¹, Nathan Felix ¹, Mimi Zhou ², Sunil Nagpal ¹ and Navin Rao ¹, ¹Janssen R&D, Spring House, PA, ²Janssen R&D, La Jolla, CA
Background/Purpose: The activation of T helper cells requires cognate recognition of antigen-derived peptides presented by Major Compatibility Complex Class II (MHC II) molecules, which are…
Abstract Number: 1057 • 2018 ACR/ARHP Annual Meeting
Autophagy Promotes Citrullination of Vimentin and Its Interaction with Major Histocompatibility Complex Class II in Synovial Fibroblasts
Eri Sugawara, Masaru Kato, Yuki Kudo, WenShi Lee, Yuichiro Fujieda, Toshiyuki Bohgaki, Olga Amengual, Kenji Oku, Shinsuke Yasuda and Tatsuya Atsumi, Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Background/Purpose: Citrullinated vimentin (cVIM) is one of the major autoantigens in patients with rheumatoid arthritis (RA), recognized by anti-citrullinated peptide antibodies. Autophagy is a self-cannibalism…
Abstract Number: 1348 • 2018 ACR/ARHP Annual Meeting
Quantitative High Throughput Screening of Small Molecules to Inhibit Interferon-Stimulated Major Histocompatibility Complex Class I in Myositis Muscle
Travis Kinder, Patricia Dranchak and James Inglese, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD
Background/Purpose: Common molecular and histological features of idiopathic inflammatory myopathies (myositis) include activation of the type 1 interferon (IFN) response and aberrant expression of major…
Abstract Number: 919 • 2017 ACR/ARHP Annual Meeting
HLA Type Imputation in the Genome Research in African American Scleroderma Patients (GRASP) Cohort Reveals Strong Associations of African Ancestry MHC Class II Types with Scleroderma and Lack of Class I HLA Type Associations
Elaine F. Remmers¹, Pravitt Gourh², Steven Boyden³, Nadia D. Morgan⁴, Ami A. Shah⁴, Adebowale Adeyemo¹, Amy Bentley¹, Mary A. Carns⁵, Settara C. Chandrasekharappa¹, Lorinda Chung⁶, Lindsey A. Criswell⁷, Chris T. Derk⁸, Robyn T. Domsic⁹, Ayo Doumatey¹, Heather Gladue¹⁰, Avram Goldberg¹¹, Jessica K. Gordon¹², Vivien M Hsu¹³, Reem Jan¹⁴, Dinesh Khanna¹⁵, Maureen D. Mayes¹⁶, Thomas A. Medsger Jr.¹⁷, Paula S. Ramos¹⁸, Marcin A. Trojanowski¹⁹, Lesley A. Saketkoo²⁰, Elena Schiopu¹⁵, Victoria K. Shanmugam²¹, Daniel Shriner¹, Richard M. Silver²², Virginia D. Steen²³, Antonia Valenzuela²⁴, John Varga²⁵, Charles Rotimi¹, Fredrick M. Wigley²⁶, Francesco Boin²⁷ and Daniel L. Kastner²⁸, ¹National Institutes of Health (NIH), National Human Genome Research Institute, Bethesda, MD, ²NIAMS-Rheumatology, National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ³National Institutes of Health (NIH), National Institute on Deafness and Other Communication Disorders, Bethesda, MD, ⁴Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁶Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁷Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁸Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁰Rheumatology, Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ¹¹NYU Langone Medical Center, New York, NY, ¹²Rheumatology, Hospital for Special Surgery, New York, NY, ¹³University of Medicine and Dentistry of New Jersey--Robert Wood Johnson Medical School, New Brunswick, NJ, ¹⁴Medicine, Rheumatology, University of Chicago, Chicago, IL, ¹⁵University of Michigan, Ann Arbor, MI, ¹⁶University of Texas McGovern Medical School, Houston, TX, ¹⁷Department of Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁸Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, ¹⁹Boston University School of Medicine, Boston, MA, ²⁰Rheumatology, Tulane University School of Medicine, New Orleans, LA, ²¹Rheumatology, The George Washington University, Washington, DC, ²²Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ²³Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ²⁴Stanford University School of Medicine, Stanford, CA, ²⁵Rheumatology and Dermatology, Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ²⁶Rheum Div/Mason F Lord, Johns Hopkins University, Baltimore, MD, ²⁷Rheumatology, University California, San Francisco, San Francisco, CA, ²⁸Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: The Genome Research in African American Scleroderma Patients (GRASP) consortium was created to obtain a collection of African American (AA) scleroderma patients to facilitate…
Abstract Number: 625 • 2014 ACR/ARHP Annual Meeting
Fine-Mapping Major Histocompatibility Complex Associations Identified Contribution of Multiple Class I and II HLA Genes on Risk of Psoriasis and Its Clinical Subtypes
Yukinori Okada¹, Buhm Han², Lam C. Tsoi³, Philip E. Stuart⁴, Eva Ellinghaus⁵, Trilokraj Tejasvi⁶, Vinod Chandran⁷, Fawnda Pellett⁸, Remy Pollock⁹, Anne M. Bowcock¹⁰, Gerald G. Krueger¹¹, Michael Weichenthal⁵, John J. Voorhees⁶, Proton Rahman¹², Peter K. Gregersen¹³, Andre Franke¹⁴, Rajan P. Nair⁶, Gonçalo R. Abecasis¹⁵, Dafna D. Gladman⁷, James T. Elder⁶, Paul IW. de Bakker¹⁶ and Soumya Raychaudhuri¹⁷, ¹Department of Human Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ²Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, ³Department of Biostatistics, Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, ⁴Department of Dermatology, University of Michigan Medical School, Ann Arbor, MI, ⁵Christian-Albrechts-University of Kiel, Kiel, Germany, ⁶University of Michigan Medical School, Ann Arbor, MI, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹Rheumatology, University of Toronto, Toronto, ON, Canada, ¹⁰Imperial College, London, United Kingdom, ¹¹Dermatology, University of Utah, Salt Lake City, UT, ¹²Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ¹³The Feinstein Institute for Medical Research, Manhasset, NY, ¹⁴Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany, ¹⁵University of Michigan, Ann Arbor, MI, ¹⁶University Medical Center, Utrecht, Netherlands, ¹⁷Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Psoriasis vulgaris (PsV) risk is strongly associated with genetic variation within the major histocompatibility complex (MHC) region, although its fine genetic architecture has not…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].